Onyx Pharmaceuticals to Present at the 29th Annual Canaccord Adams Global Growth Conference
Posted on: Thursday, 6 August 2009, 15:00 CDT
EMERYVILLE, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the 29th Annual Canaccord Adams Global Growth Conference on Thursday, August 13, at 10:30 a.m. Eastern Time. Interested parties may access a live webcast of the presentation on our website at:
http://www.onyx-pharm.com/view.cfm/32/Event-Calendar
It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to participate during the live webcast, a recorded replay of the presentation will be available one hour following the conclusion of the presentation through September 13, 2009.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R), a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. For more information about Onyx, visit the company's website at www.onyxpharm.com.
Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.
SOURCE Onyx Pharmaceuticals, Inc.
Source: PR Newswire
Related Articles
- Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
- Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
- New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
- Bayer and Onyx's Nexavar Improves Overall Survival in Liver Cancer Study
- Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
- SGX Pharmaceuticals Updates Date of Presentation at the BIO InvestorForum 2007
- Bayer/Onyx: Nexavar Approval in Liver Cancer on the Horizon
- Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
- Spectrum Pharmaceuticals Announces Satraplatin Data Presentation at the American Society of Clinical Oncology Prostate Cancer Symposium
- Bayer and Onyx' Nexavar Approved in Europe
 |
 |
User Comments (0)
RSS Feeds